Drugs / SGR-2921
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05961839 | Sep 2023 → Aug 2025 | acute myeloid leukemia, myelodysplastic syndrome | Schrödinger, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-08-14 | Schrödinger, Inc. | Results Schrödinger Announces Discontinuation of SGR-2921 Program schrodinger.com ↗
Patient safety is our first priority, and in light of two treatment-related deaths in the Phase 1 dose-escalation study, we have made the decision to discontinue further development of SGR-2921. |
| 2023-12-10 | Schrödinger, Inc. | Results Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting schrodinger.com ↗
The preclinical data reported show that both SGR-1505 and SGR-2921 have multiple favorable attributes and the potential for combination activity with standard-of-care agents. |
| 2023-08-02 | Schrödinger, Inc. | Regulatory Schrödinger Reports Second Quarter 2023 Financial Results schrodinger.com ↗
We are pleased to report FDA clearance of our IND application for SGR-2921, our CDC7 inhibitor, and expect to initiate a Phase 1 clinical study in patients with acute myeloid leukemia or myelodysplastic syndrome this year |
| 2022-12-12 | Schrödinger, Inc. | Results Schrödinger Presents New Preclinical Data Supporting Advancement of CDC7 Inhibitor Development Candidate, SGR-2921, at American Society of Hematology 2022 Annual Meeting schrodinger.com ↗
The data presented demonstrate that SGR-2921 exhibits strong anti-tumor activity in vivo across multiple acute myeloid leukemia (AML) models, including cell-derived xenograft models, as a monotherapy and in combination with standard of care agents. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-14 | Schrödinger, Inc. | Schrödinger Announces Discontinuation of SGR-2921 Program schrodinger.com ↗ |
| 2023-12-10 | Schrödinger, Inc. | Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting schrodinger.com ↗ |
| 2023-11-02 | Schrödinger, Inc. | Schrödinger to Present New Data for SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting schrodinger.com ↗ |
| 2023-08-02 | Schrödinger, Inc. | Schrödinger Reports Second Quarter 2023 Financial Results schrodinger.com ↗ |
| 2022-12-12 | Schrödinger, Inc. | Schrödinger Presents New Preclinical Data Supporting Advancement of CDC7 Inhibitor Development Candidate, SGR-2921, at American Society of Hematology 2022 Annual Meeting schrodinger.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGR-2921 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05961839 ↗ |
| Action | Inhibit | “inhibitor of cell division cycle 7-related protein kinase (CDC7)” NCT05961839 ↗ |
| Modality | Small molecule | “oral, small molecule inhibitor” NCT05961839 ↗ |
| Route | Oral | “SGR-2921 will be administered orally.” NCT05961839 ↗ |
| Target | CDC7 | “inhibitor of cell division cycle 7-related protein kinase (CDC7)” NCT05961839 ↗ |